http://www.proactiveinvestors.co.uk Proactiveinvestors RSS feed en Fri, 28 Jul 2017 01:30:55 +0100 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) <![CDATA[News - NetScientific's portfolio company ProAxsis secures grant for ProteaseTag technology ]]> http://www.proactiveinvestors.co.uk/companies/news/181336/netscientific-s-portfolio-company-proaxsis-secures-grant-for-proteasetag-technology-181336.html NetScientific PLC (LON:NSCI) said its portfolio company, ProAxsis, has secured a £57,390 grant for its ProteaseTag technology.

The grant will support the ProteaseTag technology, which enables the measurement of active protease biomarkers of disease, through a project called "Development of technology to support the advance of new protease therapeutics”.

Innovate UK is supplying the funding, which represents 60% of the total expected cost of the project.

READ: Netscientific portfolio company in cancer clinical trial with US drugs giant Merck & Co unit External validation of the Protease Tag technology

The project will be conducted at the company's laboratory facilities at Catalyst Inc., in Belfast. 

“We are very excited to announce that ProAxsis has been awarded this grant from the prestigious Innovate UK agency,” said Francois Martelet, chief executive of Netscientific and chairman of ProAxsis.

“The award represents external validation of the ProteaseTag technology and will enable ProAxsis to generate further clinical data, helping ProAxsis advance towards near-term value inflection and commercialisation."

]]>
Mon, 24 Jul 2017 09:26:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/181336/netscientific-s-portfolio-company-proaxsis-secures-grant-for-proteasetag-technology-181336.html
<![CDATA[Media files - NetScientific 'very pleased' to partner up with Merck for head and neck cancer trial ]]> http://www.proactiveinvestors.co.uk/companies/stocktube/7776/netscientific-very-pleased-to-partner-up-with-merck-for-head-and-neck-cancer-trial-7776.html Tue, 11 Jul 2017 12:50:00 +0100 http://www.proactiveinvestors.co.uk/companies/stocktube/7776/netscientific-very-pleased-to-partner-up-with-merck-for-head-and-neck-cancer-trial-7776.html <![CDATA[News - Netscientific portfolio company in cancer clinical trial with US drugs giant Merck & Co unit ]]> http://www.proactiveinvestors.co.uk/companies/news/180613/netscientific-portfolio-company-in-cancer-clinical-trial-with-us-drugs-giant-merck-co-unit-180613.html Transatlantic IP commercialisation group NetScientific PLC (LON:NSCI) said its portfolio company PDS Biotechnology Corp and a subsidiary of Merck & Co Inc (NYSE: MRK), MSD are embarking on a new clinical trial collaboration for metastatic head and neck cancer.

The collaboration will see the two companies evaluating in a Phase II clinical trial the combination of its Versamune-based PDS0101 immunotherapy treatment with MSD's anti-PD-1 therapy, KEYTRUDA (pembrolizumab).

WATCH: NetScientific 'very pleased' to partner up with Merck for head and neck cancer trial

The trial will focus on the safety and the efficacy of the combination treatment in patients with recurrent or metastatic head and neck cancer and high-risk human papillomavirus-16 (HPV16) infection after failure with platinum-based chemotherapy.

Versamune is a synthetic T-cell activating nanoparticle platform that has shown the ability to induce the immunological stimuli locally within the lymph nodes to recruit the powerful tumour-attacking immune cells called T-cells, and to enhance both the proliferation and potency of the trained T-cells.

It has also been demonstrated to significantly reduce the population of immune suppressive cells within the tumours in preclinical models.

PDS0101 is a combination of Versamune with harmless multi-epitope peptides derived from cancer-causing proteins of the HPV virus which are recognised by the immune system. 

READ: Netscientific granted exclusive patent in Europe for liver cancer diagnostic

PDS Biotechnology plans to evaluate PDS0101 in multiple HPV-advanced cancer and HPV pre-cancer Phase IIb clinical trials.

Collaboration validates confidence in Versamune platform's potential

NetScientific's Chief Executive Officer, Francois R. Martelet said: "We believe this exciting collaboration between PDS and Merck & Co., Inc. validates our confidence in the Versamune® platform's potential to deliver superior outcomes to cancer patients. 

"Following on from this successful agreement we look forward to commencing further clinical trials with additional commercial partners."

Details of the collaboration were not disclosed.

In May this year, NetScientific raised up to £9.9mln as a number of its portfolio start-ups race closer towards commercialisation.

]]>
Mon, 10 Jul 2017 12:19:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/180613/netscientific-portfolio-company-in-cancer-clinical-trial-with-us-drugs-giant-merck-co-unit-180613.html
<![CDATA[News - Netscientific granted exclusive patent in Europe for liver cancer diagnostic ]]> http://www.proactiveinvestors.co.uk/companies/news/180509/netscientific-granted-exclusive-patent-in-europe-for-liver-cancer-diagnostic-180509.html NetScientific PLC (LON:NSCI) portfolio company Glycotest has strengthened the protections around its new liver disease diagnostic with an exclusive patent in Europe.

It adds to patents already issued in the US, Japan  and Australia covering 50 unique glycoprotein biomarkers and related assay technology that can diagnose liver cancer and other liver diseases. 

Lead product, HCC Panel, has so far signfiicantly outperformed the current dominant blood test (AFP) in separate 208 and 127 patient head-to-head clinical studies, with further clinical validation expected over the second half of the year, said Francois Martelet, the chief executive of Netscientific and chairman of Glycotest.

NetScientific holds an 87.5% stake (67% on a fully diluted basis) in Glycotest. 

"We are very pleased to announce international strengthening of the IP landscape controlled by Glycotest in the field of liver diagnostics,” said Martelet.

“The patents provide the foundation for future value enhancement and represent a critical step on Glycotest's road to commercialisation.”

]]>
Fri, 07 Jul 2017 07:36:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/180509/netscientific-granted-exclusive-patent-in-europe-for-liver-cancer-diagnostic-180509.html
<![CDATA[News - NetScientific’s Glycotest to complete recent fundraising later this year ]]> http://www.proactiveinvestors.co.uk/companies/news/179804/netscientifics-glycotest-to-complete-recent-fundraising-later-this-year-179804.html NetScientific PLC’s (LON:NSCI) portfolio company Glycotest has confirmed that it expects to complete the series A fundraising currentyly being undertaken in the second half of this year.

The US-based diagnostics had originally hoped to have all the relevant documentation signed off by the end of this month but admitted that now looks unlikely.

NetScientific expects the delay to lead to an increase in Glycotest’s £0.5mln expected spend this year, although overall spend will still remain under £1mln.

Shares were unchanged at 49p on Monday morning.

]]>
Mon, 26 Jun 2017 08:11:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/179804/netscientifics-glycotest-to-complete-recent-fundraising-later-this-year-179804.html
<![CDATA[News - Netscientific raises up to £9.8mln as portfolio companies approach maturity ]]> http://www.proactiveinvestors.co.uk/companies/news/178340/netscientific-raises-up-to-98mln-as-portfolio-companies-approach-maturity-178340.html NetScientific PLC (LON:NSCI) is aiming to raise almost £10mln as a number of its portfolio of start-ups head towards commercialisation.

A placing and subscription at 45p will raise £8.1mln, while a further £1.5mln can come from a private placing at the discretion of the directors.

The offer is not underwritten with the price of the shares a 15% discount to the current market price.

NetScientific's actively managed portfolio companies are Vortex, Glycotest, Wanda and ProAxsis and the money will be used primarily to support their development.

Francois Martelet, Netscientific’s chief executive, said: "We are aiming to become a significant force in IP commercialisation with a focus on disruptive technologies in digital healthcare, diagnostics and therapeutics.

“The finance we have raised will allow us to continue to accelerate the investment into our portfolio of companies, several of which are approaching key commercial inflection points.

“More broadly, it will allow us to invest in new pipeline opportunities and further develop our infrastructure."

A meeting will be held at 12 June to approve the share issue.

Shares eased 7% to 49.23p.

]]>
Thu, 25 May 2017 13:37:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/178340/netscientific-raises-up-to-98mln-as-portfolio-companies-approach-maturity-178340.html
<![CDATA[News - Netscientific business Vortex Bio kicks off lung cancer proof of concept trial ]]> http://www.proactiveinvestors.co.uk/companies/news/178249/netscientific-business-vortex-bio-kicks-off-lung-cancer-proof-of-concept-trial-178249.html NetScientific PLC (LON:NSCI) portfolio company Vortex Biosciences has initiated two clinical research studies with Californian university UCLA in patients with Non-Small Cell Lung Cancer (NSCLC).

These studies are designed to provide proof of principle that biomarkers used for tumour biopsises can be adapted for circulating tumour cells (CTCs).

This first 60 patient study is intended to determine if cancer causing EGFR mutations can be identified in CTCs isolated and collected using Vortex’sVTX-1 Liquid Biopsy System from NSCLC patient samples.

The second 100 NSCLC patient study is intended to show CTCs isolated using the VTX-1 Liquid Biopsy System are compatible with the PD-L1 biomarker, which can help identify patients suitable for immunotherapy treatment.

Francois  Martelet, who is chairman of Vortex a well as being NetScientific’s chief executive, said  said: “These two proof of principle clinical research studies, in collaboration with UCLA, are a vital step in clinically validating and thus commercialising the company's first product, the VTX-1 system.”

]]>
Wed, 24 May 2017 09:18:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/178249/netscientific-business-vortex-bio-kicks-off-lung-cancer-proof-of-concept-trial-178249.html
<![CDATA[News - NetScientific portfolio company ProAxsis secures second licensing deal for its ProteaseTag technology ]]> http://www.proactiveinvestors.co.uk/companies/news/177564/netscientific-portfolio-company-proaxsis-secures-second-licensing-deal-for-its-proteasetag-technology-177564.html Healthcare investor Netscientific PLC’s (LON:NSCI) portfolio company ProAxsis has further strengthened its intellectual property portfolio after securing a second licensing agreement with the Queen’s University of Belfast.

The agreement gives ProAxsis the exclusive intellectual property rights for its ProteaseTag technology, which enables the measurement of active protease biomarkers of disease.

The new deal is expected to support ProAxsis in the development of additional point-of-care tests and assays.

NetScientific chief executive, François Martelet, said: “ProAxsis is approaching a point where it will be able to commercialise its NEATstik point of care test based on the ProteaseTags technology.

Deal ‘builds value’ of ProteaseTag

“This agreement, which strengthens the company's intellectual property portfolio, puts ProAxsis in a great position to launch further immunoassays and point of care tests and build the value of this technology.”

ProAxsis chief executive David Ribeiro added: “These modified ProteaseTags are more suited to some of our ongoing protease biomarker targets and the company looks forward to launching further immunoassays and point-of-care tests in the near future.”

Technology originally developed at Queen’s

A first licensing agreement was penned back in 2013 when ProAxsis was spun out from Queen’s, where the technology behind PoteaseTag was initially developed.

This allowed ProAxsis to commercialise its first product which measured neutrophil elastase, a leading indicator of lung infection and inflammation in patients with chronic respiratory diseases.

]]>
Wed, 10 May 2017 07:29:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/177564/netscientific-portfolio-company-proaxsis-secures-second-licensing-deal-for-its-proteasetag-technology-177564.html
<![CDATA[News - NetScientific: ProAxsis to present ProteaseTag data at ATS conference ]]> http://www.proactiveinvestors.co.uk/companies/news/177365/netscientific-proaxsis-to-present-proteasetag-data-at-ats-conference-177365.html NetScientific Plc (LON:NSCI) told investors that its portfolio company ProAxsis will present data on its ProteaseTag technology at the American Thoracic Society (ATS) Conference.

The conference takes place in Washington DC, between May 19 and May 24.

CLICK HERE: For a daily round-up of all the Proactive news

ProAxsis, which is developing products to detect protease disease biomarkers, has submitted to ATS abstracts for data relating to three products being developed by ProAxsis in chronic diseases including COPD, bronchiectasis and Cystic Fibrosis.

"The broad range of major disease indications covered in these studies demonstrates the versatility of the ProteaseTag technology being developed by ProAxsis,” said François R. Martelet, NetScientific chief executive.

“We look forward to the continued development of these exciting products and expect to see them commercially available by the end of 2017."

]]>
Fri, 05 May 2017 08:55:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/177365/netscientific-proaxsis-to-present-proteasetag-data-at-ats-conference-177365.html
<![CDATA[Media files - NetScientific chief François Martelet on the 'strong return' from sale of OncoVerse ]]> http://www.proactiveinvestors.co.uk/companies/stocktube/7327/netscientific-chief-franois-martelet-on-the-strong-return-from-sale-of-oncoverse-7327.html Mon, 24 Apr 2017 15:55:00 +0100 http://www.proactiveinvestors.co.uk/companies/stocktube/7327/netscientific-chief-franois-martelet-on-the-strong-return-from-sale-of-oncoverse-7327.html <![CDATA[News - NetScientific’s portfolio company nets “strong return” from sale of OncoVerse stake ]]> http://www.proactiveinvestors.co.uk/companies/news/176773/netscientifics-portfolio-company-nets-strong-return-from-sale-of-oncoverse-stake-176773.html Healthcare and biomedical investor Netscientific PLC's (LON:NSCI) portfolio company Wanda has sold off its stake in OncoVerse LLC for an undisclosed sum.

The sale to BTG plc (LON:BTG) represents a “strong return” on NetScientific’s initial investment and a “successful exit” from the first downstream application from Wanda, NetScientific said.

WATCH: Netscientific boss on "strong return" from OncoVerse sale CLICK HERE to sign up to the Proactive daily newsletter

OncoVerse is a digital health platform which allows cancer patients’ care teams to collaborate and also allows clinicians across all disciplines to work together to establish the most effective treatment plan for their patients.

“We believe the OncoVerse platform will become a leading tool in the management of cancer patients and we are proud to have been involved in helping bring it to maturity,” said NetScientific chief executive François Martelet.

“The sale of the equity to BTG represents a strong return on NetScientific's initial investment, and underscores Wanda's unique expertise in creating tools which can support informed treatment decisions.”

Dignity Health, which has been a co-investor from OncoVerse’s inception, will continue to be a shareholder alongside BTG.

As far as Wanda is concerned, Martelet said NetScientific will continue to support it as it looks for new “promising opportunities” in the remote health management space.

Shares opened 4.5% higher at 57p on Monday.

]]>
Mon, 24 Apr 2017 08:03:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/176773/netscientifics-portfolio-company-nets-strong-return-from-sale-of-oncoverse-stake-176773.html
<![CDATA[News - NetScientific to focus on enhancing value of portfolio this year ]]> http://www.proactiveinvestors.co.uk/companies/news/175822/netscientific-to-focus-on-enhancing-value-of-portfolio-this-year-175822.html NetScientific PLC (LON:NSCI) said after a year of development, the focus in 2017 will be on boosting the value of its healthcare companies portfolio.

“We focused on delivering the individual development milestones within each of our portfolio companies, paving the way in 2017 for continued progress and maturation of our investments,” said Francois Martelet, chief executive officer of NetScientific.

Much of the effort this year will go on enhancing the competitiveness and value of the existing individual portfolio companies, though the board will also continue to evaluate new pipeline opportunities.

Preparing for lift-off

As an incubator fund, a lot of the companies in the NetScientific portfolio are in the pre-revenue stage, so it should be no surprise that the company posted a loss of 2016, though at £12.39mln the loss was less than the £14.72mln loss analysts were predicting, albeit wider than the £10.42mln loss registered in 2015.

Revenue in 2016 was a nominal £518,000, up from £21,000 the year before.

A number of the group’s portfolio companies are either in the early stages of commercialising their IP or are poised to enter it. Indeed, Vortex Biosciences, which is developing a novel liquid biopsy technology that aims to revolutionise cancer diagnosis, launched its first product, the VTX-1 instrument, at Tri-Conference on Molecular Medicine on 21 February 2017.

Read NetScientific hails commercial launch of breakthrough cancer detection device Read NetScientific buoyed by Vortex’s tech endorsement

Cash on the balance sheet as at 31 December 2016 was £9.5 million (2015: £23.2 million). Cash used in operations, was £12.9 million (2015: £10.7 million).

“We continue to believe that we have a world-class portfolio of companies, experienced and relevant management teams and the business and financing strategies to support their development and attract the necessary third-party validation capital,” said Sir Richard Sykes, non-executive chairman of the group.

Shares in NetScientific fell 5.5p to 52p on the release of the results.

]]>
Mon, 03 Apr 2017 08:21:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/175822/netscientific-to-focus-on-enhancing-value-of-portfolio-this-year-175822.html
<![CDATA[News - NetScientific buoyed by Vortex’s tech endorsement ]]> http://www.proactiveinvestors.co.uk/companies/news/175778/netscientific-buoyed-by-vortexs-tech-endorsement-175778.html Healthcare and biomedical investor NetScientific plc  (LON:NSCI) is making considerable strides in 2017.

The firm commercialises intellectual property (IP) through developing early and mid-stage healthcare firms focused on diagnostics and digital health.

The big  players in its portfolio are Wanda, Vortex Biosciences, Glycotest and ProAxsis.

Vortex in focus..

In focus and growing over the  last year have been Vortex - a California based cancer circulating cells specialist and Wanda - an analytics software group, whose aim is to reduce US hospital admissions.

Recent big news has centred around the  former, Vortex, in which Netscientific has pumped in over £13mln and owns 95%.

Last month begun the milestone commercial launch of its VTX1 Liquid Biopsy System - the first time Netscientific has been able to market a cancer diagnostic instrument.

The tech offers a breakthrough in early cancer detection in that it is able to collect circulating tumour cells (CTC) from the bloodstream that provide the tell-tale sign of the killer disease.

François Martelet, NetScientific's chief executive and  chairman of Vortex said: "We believe that CTC technology will increasingly feature in ground-breaking work to enhance our understanding of cancer."

This belief has been backed up by recent  research papers. One lauds its use to capture CTCs in a preliminary step to performing a single-CTC Western blot test by researchers at three US universities.

Such a test is often used as a follow-up to confirm the presence of an antibody to help diagnosis.

Meanwhile, data to be presented at the American Association for Cancer Research  will demonstrate its use to collect  populations of CTCs for colorectal cancer, non-small cell lung cancer (NSCLC), breast cancer and drug testing research.

Vortex has registered a Class I medical device with the US FDA (Food and Drug Administration) and established a CE Mark for the proprietary technology.

At ProAxis

At ProAxsis last November, its medical diagnostics company, the firm successfully registered a CE Mark for its novel ProteaseTag Active Neutrophil Elastase Immunoassay, allowing it to proceed to the commercialisation stage of its biochemical test in the European Union.

At Glycotest

Glycotest is a US-based liver diagnostics company seeking to commercialise new and unique blood tests for life threatening liver cancers and fibrosis-cirrhosis with exclusive worldwide rights to more than 50 patent-protected serum protein biomarkers.

A clinical study of its lead product, HCC Panel, has shown the product’s ability to detect early-stage liver cancer significantly better than the alpha-fetoprotein blood test, which is the current standard in healthcare.

At Wanda

Wanda is a San Francisco-based digital health company, which has developed a way to digitally monitor people with congestive heart failure and other chronic conditions, so that specialists can monitor risk and lower readmissions.

The latter is significant because in the US the system means hospitals have to pay when patents are discharged then re-admitted.

Last year it signed a contract with a leading US high-tech home nursing and therapy services agency, Health Resource Solutions (HRS), for the use of its chronic condition management product.

It also signed a collaborative agreement with the fifth largest health provider organisation in the US, Dignity Health, to launch its new oncology platform, Oncoverse.

The platform allows clinicians to work together to establish the most effective treatment plan and helps to reduce administration costs.

The firm has also launched myWanda, the only mobile application specifically aimed at empowering women to improve the health of their hearts.

At PDS Biotechnology

At the tail end of 2016, Netscientific upped its stake in another of its firms -  PDS Biotechnology -  to 14.6%.

This is  a developer of cancer immunotherapies ( an area of medicine attracting much excitement) and vaccines for infectious diseases by exercising warrants for 1.39mln shares. It has now put US$3.5ln into PDS.

Its cancer treatment pipeline includes compounds for prostate, ovarian, breast and colorectal cancers, in addition to its lead PDS0101 programme for several HPV-related cancers – HPV, or human papillomavirus, being a virus that infects the skin and the cells lining body cavities.

PDS has positive phase I/IIa trial data under its belt and, significantly, has agreed partnership funding from the National Institute of Health and MD Anderson for three phase II clinical trials.

]]>
Fri, 31 Mar 2017 14:25:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/175778/netscientific-buoyed-by-vortexs-tech-endorsement-175778.html
<![CDATA[News - Vortex technology further endorsed in recent papers, says NetScientific ]]> http://www.proactiveinvestors.co.uk/companies/news/175734/vortex-technology-further-endorsed-in-recent-papers-says-netscientific-175734.html The circulating tumour cell (CTC) capture technology  by NetScientific PLC'S (LON:NSCI) investee company Vortex Biosciences has been further endorsed in two research papers.

As reported last month, the firm has begun the commercial launch of its VTX1 Liquid Biopsy System, which offers a breakthrough in early cancer detection.

The recent study published in  'Nature Communications' describes the use of Vortex technology to capture CTCs in a preliminary step to performing a single-CTC Western blot test by researchers at three US universities.

READ - NetScientific hails commercial launch of breakthrough cancer detection device WATCH - NetScientific boss proud of cancer diagnostic tool's achievements

Such a test is often used as a follow-up to confirm the presence of an antibody to help diagnosis.

The study showed the Vortex test provided a unique targeted proteomics approach to understanding CTC cancer biology.

Meanwhile, data to be presented at the American Association for Cancer Research between 1 and 5 April will demonstrate the ability of Vortex's technology to rapidly collect highly enriched populations of CTCs, undamaged by labels or reagents, for colorectal cancer, non-small cell lung cancer (NSCLC), breast cancer and drug testing research.

François R. Martelet, NetScientific's chief executive and  chairman of Vortex Biosciences, said: "We are proud to see Vortex progress its VTX-1 system to demonstrate its simplicity and performance representing the next step in CTC isolation, whilst enabling cancer researchers to directly access the cancer biology of the patient.

"We believe that CTC technology will increasingly feature in ground-breaking work to enhance our understanding of cancer.

AIM-listed Netscientific owns 95% of Vortex having invested just over £13mln in the business.

]]>
Fri, 31 Mar 2017 07:34:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/175734/vortex-technology-further-endorsed-in-recent-papers-says-netscientific-175734.html
<![CDATA[Media files - NetScientific boss proud of cancer diagnostic tool's achievements ]]> http://www.proactiveinvestors.co.uk/companies/stocktube/6974/netscientific-boss-proud-of-cancer-diagnostic-tool-s-achievements-6974.html Thu, 23 Feb 2017 07:49:00 +0000 http://www.proactiveinvestors.co.uk/companies/stocktube/6974/netscientific-boss-proud-of-cancer-diagnostic-tool-s-achievements-6974.html <![CDATA[News - NetScientific hails commercial launch of breakthrough cancer detection device ]]> http://www.proactiveinvestors.co.uk/companies/news/173518/netscientific-hails-commercial-launch-of-breakthrough-cancer-detection-device-173518.html Wed, 22 Feb 2017 07:21:00 +0000 http://www.proactiveinvestors.co.uk/companies/news/173518/netscientific-hails-commercial-launch-of-breakthrough-cancer-detection-device-173518.html <![CDATA[News - NetScientific hails award-winning scientist ]]> http://www.proactiveinvestors.co.uk/companies/news/173180/netscientific-hails-award-winning-scientist-173180.html NetScientific PLC (LON:NSCI), the healthcare investment group, said the chief scientific officer of one of its investee companies has won industry recognition.

Vortex Biosciences' Elodie Sollier-Christen received the 2017 Society award for Laboratory Automation and Screening Innovation.

Her presentation to the judges was entitled Vortex Technology for fast and label-free isolation of circulating tumour cells from blood samples.

In it she discussed a breakthrough by Vortex in the isolation of circulating tumour cells from blood samples.

NetScientific chief executive François Martelet said: "We wish to extend our warm congratulations to Elodie on her receipt of this prestigious award.

“We view this prize as a recognition of her extraordinary work on the cutting edge technology utilised by  Vortex on the design of the VTX-1 liquid biopsy system.

“We believe that this technology has great potential to significantly impact laboratory automation and screening and we are delighted to see it receive due recognition."

]]>
Wed, 15 Feb 2017 07:54:00 +0000 http://www.proactiveinvestors.co.uk/companies/news/173180/netscientific-hails-award-winning-scientist-173180.html
<![CDATA[News - NetScientific announces new CEO for portfolio company Wanda ]]> http://www.proactiveinvestors.co.uk/companies/news/170718/netscientific-announces-new-ceo-for-portfolio-company-wanda-170718.html NetScientific PLC (LON:NSCI), the backer of fledgling healthcare companies, said digital health company Wanda has a new chief executive officer.

Foad Dabiri, who has been Wanda’s chief technology officer since March 2014, will be taking over from Steve Curd as chief executive officer (CEO) with immediate effect.

Curd had been Wanda’s CEO since September 2015.

Dabiri will take the company through its commercialisation stage, said NetScientific.

"Foad's unique understanding of the nexus between predictive analytics, data and patient need, make him the best person to lead Wanda at this critical juncture as it moves into its commercialisation phase,” said François Martelet, who is CEO of NetScientific and chairman of Wanda.

San Francisco-based Wanda is one of NetScientific’s portfolio companies.

It is dedicated to advancing the effectiveness and efficiency of medicine by using machine learning in place of conventional technologies and by enabling clinicians to make more informed care decisions.

]]>
Tue, 20 Dec 2016 07:42:00 +0000 http://www.proactiveinvestors.co.uk/companies/news/170718/netscientific-announces-new-ceo-for-portfolio-company-wanda-170718.html
<![CDATA[News - NetScientific provides more backing for cancer immunotherapies developer ]]> http://www.proactiveinvestors.co.uk/companies/news/170588/netscientific-provides-more-backing-for-cancer-immunotherapies-developer-170588.html NetScientific PLC (LON:NSCI) has upped its stake in PDS Biotechnology, a developer of cancer immunotherapies and vaccines for infectious diseases.

The Aim-listed firm exercised warrants for 1.39mln shares at a cost of US$687,493.

NetScientific has now invested a total of US$3.5ln in PDS Biotechnology, giving it a 14.6% stake.

PDS is operating in the exciting area of immuno-oncology – activating the body's own immune system to recognise and destroy cancer cells.

The field has caused a lot of excitement in the medical world, but one of the major drawbacks has been reports of debilitating toxicities – a drawback PDS has conquered with its Versamune T-cell (a type of white blood cell) activating platform.

PDS's cancer treatment pipeline includes compounds for prostate, ovarian, breast and colorectal cancers, in addition to its lead PDS0101 programme for several HPV-related cancers – HPV, or human papillomavirus, being a virus that infects the skin and the cells lining body cavities.

PDS has positive phase I/IIa trial data under its belt and has agreed partnership funding from the National Institute of Health and MD Anderson for three phase II clinical trials.

Shares in NetScientific rose 2.3% to 67p on the news.

]]>
Fri, 16 Dec 2016 08:18:00 +0000 http://www.proactiveinvestors.co.uk/companies/news/170588/netscientific-provides-more-backing-for-cancer-immunotherapies-developer-170588.html
<![CDATA[Media files - NetScientific plc chief hails progress at Vortex Biosciences ]]> http://www.proactiveinvestors.co.uk/companies/stocktube/6340/netscientific-plc-chief-hails-progress-at-vortex-biosciences-6340.html Mon, 07 Nov 2016 09:15:00 +0000 http://www.proactiveinvestors.co.uk/companies/stocktube/6340/netscientific-plc-chief-hails-progress-at-vortex-biosciences-6340.html <![CDATA[News - NetScientific shares gain as Vortex makes commercialisation progress ]]> http://www.proactiveinvestors.co.uk/companies/news/168536/netscientific-shares-gain-as-vortex-makes-commercialisation-progress-168536.html NetScientific plc (LON:NSCI) shares nudged higher as it revealed portfolio company Vortex Biosciences had moved closer to selling its circulating tumour cell (CTC) capture system in the USA and Europe.

Vortex has registered a Class I medical device with the US FDA (Food and Drug Administration) and established a CE Mark for the proprietary technology.

NetScientific's chief executive and chairman of Vortex, Francois Martelet, said: "Both the CE Mark and FDA Class 1 registration are significant milestones achieved towards making VTX-1 commercially available in early 2017 and bringing us closer to the sale of the system in the clinical market in the US."

The CE Mark allows Vortex to install systems in the European Economic Area (EEA).

It will initially be distributed for research use only. The FDA Class 1 registration is a first step towards the sale of the system in the clinical market

The Vortex VTX-1 liquid biopsy system is a fully automated benchtop system for collecting intact CTCs.

CTCs, shed by cancer tumors, can potentially allow for better characterisation of the disease, resulting in better treatment decisions.

Cancer cells are traditionally obtained through tissue biopsies but these are costly, painful, often not possible.

Shares added 6.3% to stand at 67.5p.

]]>
Fri, 04 Nov 2016 08:43:00 +0000 http://www.proactiveinvestors.co.uk/companies/news/168536/netscientific-shares-gain-as-vortex-makes-commercialisation-progress-168536.html
<![CDATA[News - Vortex Bio gains FDA registration for Class 1 medical device ]]> http://www.proactiveinvestors.co.uk/companies/news/168502/vortex-bio-gains-fda-registration-for-class-1-medical-device-168502.html Vortex Biosciences, a provider of circulating tumor cell (CTC) capture systems, Thursday announced it has registered a Class I medical device with the US Food and Drug Administration and established a CE Mark for its proprietary CTC capture system, the VTX-1 Liquid Biopsy System.

Vortex is a portfolio company of the UK’s NetScientific plc (AIM:NSCI, LON:NSCI), the transatlantic healthcare IP commercialisation group.

"Both the CE Mark and FDA Class 1 registration are significant milestones achieved towards making VTX-1 commercially available in early 2017 and bringing us closer to the sale of the system in the clinical market in the US," said Chief Executive Officer and Chairman of Vortex, Francois R. Martelet.

The CE Mark allows Vortex to install systems in the European Economic Area (EEA). VTX-1 will initially be distributed into the Research Use Only (RUO) market. The FDA Class 1 registration is a first step towards the sale of the system in the clinical market.

A CE mark indicates the VTX-1 has met all applicable directives of the European Commission (EC) and subsequently the laws and regulations of the European Union (EU) member states and therefore can be commercialized within the 30-nation EEA and Switzerland. The establishment of this CE mark involved thorough evaluation and testing of the VTX-1 to assure it performs safely and as designed.  The FDA Class 1 registration ensures we are operating within FDA guidelines for the use of the system.

Representative of cancer status in the patient, CTCs, shed by tumors, can potentially allow for better characterisation of the disease, resulting in more informed treatment decisions. Cancer cells are traditionally obtained through tissue biopsies. Biopsies are costly, painful, often not possible, and cannot be performed on all possible tumor sites.

CTCs offer tremendous potential, but are relatively scarce, with concentrations as low as 1-10 CTCs/mL of whole blood, against a background of millions of white blood cells and billions of red blood cells. Capturing CTCs out of whole blood is a critical step in utilising CTCs for cancer diagnosis, better cancer treatment decisions and disease monitoring.

The Vortex VTX-1 Liquid Biopsy System is a fully automated benchtop system for collecting intact CTCs using microfluidic technology. Inside the VTX-1 chip, unlabeled CTCs in whole blood are trapped in microscale vortices while smaller red and white blood cells pass through. After selective trapping into the microfluidic chambers, CTCs can be flushed and collected into a variety of containers for downstream analysis.

The Vortex CTC isolation process is label-free and contact-free, keeping CTCs intact and viable. Samples processed by the VTX-1 minimize white blood cell contamination, resulting in a highly pure CTC sample with minimal white blood cell contamination.

]]>
Thu, 03 Nov 2016 16:05:00 +0000 http://www.proactiveinvestors.co.uk/companies/news/168502/vortex-bio-gains-fda-registration-for-class-1-medical-device-168502.html
<![CDATA[News - NetScientific's Vortex Biosciences has new director ]]> http://www.proactiveinvestors.co.uk/companies/news/168095/netscientific-s-vortex-biosciences-has-new-director-168095.html NetScientific PLC (LON:NSCI) said portfolio firm and circulating tumor cell group  Vortex Biosciences has hired Deborah Neff as a non-executive director.

She will play a critical role providing strategic oversight, as its circulating tumor cell enrichment system, the VTX-1, is progressed towards commercialisation, Netscientific said.

Neff has served in a number of leadership positions in healthcare companies, including a 15-year career at Becton Dickinson & Co in executive management positions,

The planned commercial launch of the VTX-1 system is planned for the first quarter of 2017.

It is a fully automated benchtop system for capturing intact circulating tumor cells (CTCs) directly from whole blood samples without any preprocessing steps.

CTCs, shed by cancer tumors, can potentially reveal disease recurrence or disease progression earlier than imaging and more reliably compared with standard biomarkers.

]]>
Wed, 26 Oct 2016 14:59:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/168095/netscientific-s-vortex-biosciences-has-new-director-168095.html
<![CDATA[Media files - NetScientific’s ProAxsis sees big European market open up; next stop: USA ]]> http://www.proactiveinvestors.co.uk/companies/stocktube/6079/netscientifics-proaxsis-sees-big-european-market-open-up-next-stop-usa-6079.html Fri, 30 Sep 2016 14:48:00 +0100 http://www.proactiveinvestors.co.uk/companies/stocktube/6079/netscientifics-proaxsis-sees-big-european-market-open-up-next-stop-usa-6079.html <![CDATA[News - NetScientific celebrates CE mark breakthrough for its ProAxsis unit ]]> http://www.proactiveinvestors.co.uk/companies/news/166736/netscientific-celebrates-ce-mark-breakthrough-for-its-proaxsis-unit-166736.html NetScientific PLC (LON:NSCI) said ProAxsis, its medical diagnostics company, has successfully registered a CE Mark for its novel ProteaseTag Active Neutrophil Elastase Immunoassay.

The healthcare intellectual property commercialisation group said the breakthrough will enable its Northern Ireland-based portfolio company to proceed to the commercialisation stage of its biochemical test in the European Union.

“We are delighted that ProAxsis has achieved a significant milestone in successfully CE marking its novel ProteaseTag Active Neutrophil Elastase Immunoassay for chronic respiratory diseases. This will help accelerate its commercialisation in the COPD and Cystic Fibrosis markets,” said François Martelet, chairman of ProAxsis and chief executive officer of NetScientific.

"ProAxsis is now able to sell its immunoassay in the 28 member states of the European Union, as well as Switzerland, Turkey, Iceland, Norway and Liechtenstein. Achieving CE Mark for its immunoassay demonstrates the company's clear commitment to delivering first-class quality products to physicians and their patients who suffer from chronic respiratory diseases," Martelet said.

Dr David Ribeiro, chief executive officer of ProAxsis, said the company had already had enquiries from a number of pharmaceutical companies concerning the commercial use of the immunoassay in their upcoming clinical trials.

]]>
Fri, 30 Sep 2016 07:34:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/166736/netscientific-celebrates-ce-mark-breakthrough-for-its-proaxsis-unit-166736.html
<![CDATA[Media files - NetScientific PLC focused on “execution, execution and execution” ]]> http://www.proactiveinvestors.co.uk/companies/stocktube/6053/netscientific-plc-focused-on-execution-execution-and-execution-6053.html Tue, 27 Sep 2016 15:35:00 +0100 http://www.proactiveinvestors.co.uk/companies/stocktube/6053/netscientific-plc-focused-on-execution-execution-and-execution-6053.html <![CDATA[News - NetScientific revitalised by focus on core portfolio ]]> http://www.proactiveinvestors.co.uk/companies/news/166510/netscientific-revitalised-by-focus-on-core-portfolio-166510.html Pre-revenue healthcare intellectual property (IP) commercialisation group NetScientific PLC (LON:NSCI) said its core portfolio companies made excellent progress in the first half of 2016.

The big four players in NetScientific’s roster are: Wanda, Vortex Biosciences, Glycotest and ProAxsis.

Wanda

Wanda is a San Francisco-based digital health company focused on reducing hospitalisation risk and improving the quality of life for those suffering chronic conditions.

It has developed a way to digitally monitor people with congestive heart failure and other chronic conditions, so that specialists can monitor risk and lower readmissions. The latter is significant because in the US the system means hospitals have to pay when patents are discharged then re-admitted.

During the reporting period it signed a contract with a leading US high-tech home nursing and therapy services agency, Health Resource Solutions (HRS), for the use of its chronic condition management product. HRS looks after more than 1,000 patients per month helping them to have a higher quality of life at home rather than in hospitals. The agreement is demonstrating early signs of commercial success, NetScientific said.

In addition, Wanda signed a collaborative agreement with the fifth largest health provider organisation in the US, Dignity Health, to launch its new oncology platform, Oncoverse. The platform allows clinicians to work together to establish the most effective treatment plan and helps to reduce administration costs.

Post-reporting period Wanda has broadened its commercialisation strategy to include a direct-to-consumer offering with the launch of myWanda, the only mobile application specifically aimed at empowering women to improve the health of their hearts.

The group said the app is already attracting interest from large employers.

Vortex Biosciences

Vortex Biosciences is a US based cancer diagnostic company, developing a novel liquid biopsy automated instrument, VTX-1, and microfluidic cartridge for the isolation of circulating tumour cells from whole blood without the need for any pre-processing of the blood.

In the first half of 2016, the VTX-1 instrument and the integrated microfluidic cartridge moved from feasibility into late stage development. The aim is for a commercial launch into the clinical research market in the first quarter of next year.

Glycotest

Glycotest is a US-based liver diagnostics company seeking to commercialise new and unique blood tests for life threatening liver cancers and fibrosis-cirrhosis with exclusive worldwide rights to more than 50 patent-protected serum protein biomarkers.

A clinical study of its lead product, HCC Panel, demonstrated the product’s ability to detect early-stage liver cancer significantly better than the alpha-fetoprotein blood test, which is the current standard in healthcare.

ProAxsis

ProAxsis is a Northern Ireland-based medical diagnostics company, developing a range of laboratory assays and point-of-care tests designed for the capture, detection and measurement of active protease biomarkers of diseases.

NetScientific said ProAxsis continued to make excellent progress in the first half of the year with its ProteaseTag Active Neutrophil Elatase Immunoassay, which was increasingly being used by academic research centres and pharmaceutical companies focused on respiration issues.

Management comment

"NetScientific has undergone a transformation under the leadership of François Martelet, with the rationalisation of the portfolio and restructuring of the management team, resulting in a streamlined group focused on IP commercialisation,” said Sir Richard Sykes, executive chairman of NetScientific, adding that the portfolio focus has been totally revitalised.

Chief executive Martelet said: "During the period I am delighted to say that four of our core portfolio companies made significant operational and development progress, positioning themselves optimally to initiate external financing rounds with the goal of providing significant value inflection points upon completion."

The group has ambitions to strengthen its transatlantic focus through organic and strategic growth, actively managing the portfolio and replenishing the pipeline with disruptive chronic disease opportunities, it said.

Delivering near-term milestones remains a focus with key deliverables including: completing external financing for Wanda/Glycotest, a product launch for Vortex and ProAxsis achieving a CE mark for its NEATstik point-of-care device.

Numbers are not particularly meaningful for a company at this stage of development, but for the record revenue in the first half of 2016 grew to £359,243 from £55,000 the year before, while the loss before tax widened to £6.13mln from £4.39mln.

Available cash at the end of June had diminished to £15.9mln from £23.2mln at the end of 2015.

 

]]>
Tue, 27 Sep 2016 14:42:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/166510/netscientific-revitalised-by-focus-on-core-portfolio-166510.html
<![CDATA[News - NetScientific’s Wanda chosen by 24Hr HomeCare ]]> http://www.proactiveinvestors.co.uk/companies/news/166382/netscientifics-wanda-chosen-by-24hr-homecare-166382.html Netscientific PLC’s (LON:NSCI) portfolio company Wanda will supply its home-centred care technology to LA-based care services firm 24Hr HomeCare.

24Hr HomeCare will use Wanda’s predicative analytics and behavioural guidance technology to improve outcomes for at-risk patients and reduce hospital readmissions.

"24Hr HomeCare's decision to use Wanda's home-centred care technology…is an excellent endorsement of Wanda's growing reputation as a digital healthcare technology,” said NetScientific chief executive François Martelet.

LA-based 24Hr HomeCare said it will deploy the technology immediately, adding that it would be “a huge asset” by allowing the company to monitor patients between visits.

There were other options on the table, 24Hr HomeCare said, but Wanda’s offering “stood out”.

As well as allowing for the remote monitoring of patients, Wanda’s technology can predict a patient’s future health, by providing an “advanced look into the patient’s most likely future”.

Shares in NetScientific were up 12% to 84.5p. 

]]>
Fri, 23 Sep 2016 10:34:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/166382/netscientifics-wanda-chosen-by-24hr-homecare-166382.html
<![CDATA[News - NetScientific's Glycotest granted Japanese patent for liver disease test ]]> http://www.proactiveinvestors.co.uk/companies/news/165709/netscientific-s-glycotest-granted-japanese-patent-for-liver-disease-test-165709.html NetScientific plc's (LON:NSCI) portfolio company Glycotest, has been granted a Japanese patent for its core technology for the early detection of life threatening liver disease.

The patent joins five others previously granted across Australia, US and Japan, covering the use of over 50 unique glycoprotein biomarkers for the diagnosis of liver cancers and diseases.

The group said it soon expects to announce positive developments in the patent protection of the proprietary assay technology required to measure these novel biomarkers.

Glycotest is a private liver disease diagnostics platform commercialising novel clinical laboratory testing services to detect liver cancers and diseases, such as fibrosis-cirrhosis.

Chief executive Lawrence Cohen said the group's intellectual property portfolio along with outstanding clinical results achieved to date had potential to form the base of what it expected to be a very strong company in liver disease diagnostics.

"The Glycotest patent portfolio is becoming substantial and we expect more good news in the coming year regarding our intellectual property position," he said.

]]>
Mon, 12 Sep 2016 08:13:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/165709/netscientific-s-glycotest-granted-japanese-patent-for-liver-disease-test-165709.html
<![CDATA[News - NetScientific’s Wanda appoints new non-exec ]]> http://www.proactiveinvestors.co.uk/companies/news/163637/netscientifics-wanda-appoints-new-non-exec-163637.html Netscientific PLC’s (LON:NSCI) digital health portfolio company Wanda has told investors that it has appointed Derek Newell to its board as a non-executive director.

Newell is currently the chief executive of enterprise health benefits platform, Jiff, and Wanda has brought him on board to take advantage of his extensive experience in the healthcare sector.

On top of his role at Jiff, he was previously the president and chief executive at Robert Bosch Healthcare, chief executive at Health Hero Networks and has also worked for LifeMasters.

"Derek is a highly regarded and knowledgeable industry leader with vast experience in the field of innovative health technology,” said NetScientific chief executive and Wanda chairman François Martelet.

“We are delighted that Wanda has further strengthened its Board with a digital health expert of his calibre."

Wanda chief executive Steve Curd echoed those thoughts, explaining: “I am confident that Derek will offer tremendous insights and provide us with a unique perspective as we continue to advance our technical, operational, and financial objectives."

Shares in NetScientific were down 2%, or 1.5p, to 72p.

]]>
Thu, 08 Sep 2016 08:16:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/163637/netscientifics-wanda-appoints-new-non-exec-163637.html
<![CDATA[Media files - Netscientific PLC chief executive very excited about heart health phone app ]]> http://www.proactiveinvestors.co.uk/companies/stocktube/5422/netscientific-plc-chief-executive-very-excited-about-heart-health-phone-app-5422.html Fri, 19 Aug 2016 13:37:00 +0100 http://www.proactiveinvestors.co.uk/companies/stocktube/5422/netscientific-plc-chief-executive-very-excited-about-heart-health-phone-app-5422.html <![CDATA[News - App-y days as NetScientific’s portfolio company Wanda launches phone app ]]> http://www.proactiveinvestors.co.uk/companies/news/129497/app-y-days-as-netscientifics-portfolio-company-wanda-launches-phone-app-129497.html Netscientific PLC's (LON:NSCI) digital health portfolio company Wanda has launched a phone app today aimed at helping women improve the health of their hearts.

MyWanda, the first app of its kind, will offer personalised daily tips, advice and inspiration to encourage women to develop “heart healthy behaviours”.

“We’re excited to bring a technology solution to market that can truly inform, motivate and support women to take better care of their hearts,” said Wanda chief executive Steve Curd.

NetScientific’s chief executive François Martelet added: “This is an important milestone for Wanda and is in line with the company’s strategy to expand its platform of mobile applications to capture patients earlier in their disease trajectory.”

Heart disease is the number one killer of women in America, although San Francisco-based Wanda estimates that around 80% of cases are preventable through education and lifestyle changes.

The company has called the new app, which is available on the US iTunes App Store, a “revolution in healthcare”.

As well as helping women to take control of their health, the app will add to Wanda’s current data and understanding of women’s heart health.

Shares in NetScientific were down 1p, or 1.3%, to 76p.

]]>
Fri, 19 Aug 2016 07:41:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/129497/app-y-days-as-netscientifics-portfolio-company-wanda-launches-phone-app-129497.html
<![CDATA[News - NetScientific appoints new scientific advisory board ]]> http://www.proactiveinvestors.co.uk/companies/news/129450/netscientific-appoints-new-scientific-advisory-board-129450.html Healthcare technology group NetScientific plc (LON:NSCI) has made a number of appointments to its newly formed scientific advisory board (SAB) at its portfolio company Vortex Biosciences.

The board comprises of distinguished clinicians and bioengineers in the field of oncology and circulating tumour cells (CTC).

It will provide strategic guidance in decision-making to support the development and commercialization of Vortex's CTC enrichment system for both the research and diagnostic markets.

"We are thrilled to have attracted some of the world's leading experts in circulating tumor cells, oncology, clinical trials and microfluidics to help us define our clinical strategy as we commercialize our next generation CTC enrichment system, the VTX-1," said Vortex chief executive Gene Walther.

"The formation of our SAB serves as an endorsement of the scientific and clinical enthusiasm for the Vortex technology."

]]>
Thu, 18 Aug 2016 07:58:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/129450/netscientific-appoints-new-scientific-advisory-board-129450.html
<![CDATA[News - NetScientific investee company strikes Harvard licensing deal ]]> http://www.proactiveinvestors.co.uk/companies/news/128945/netscientific-investee-company-strikes-harvard-licensing-deal-128945.html The AIM-listed healthcare technology incubator, NetScientific PLC (LON:NSCI), said one of its investee companies had struck a deal with Harvard University.

Vortex Biosciences has been granted a series of licences for cell electroporation technology developed by Harvard researchers that will boost its ability to analyse circulation tumour cells (CTCs).

The patents will also “significantly strengthen” Vortex’s intellectual property base, NetScientific said in an announcement Wednesday.

Chief executive Francois Martelet: “The exclusive license of these new patents from a world leading research institution will significantly increase the ability of Vortex's technology to characterize CTCs and strengthen its ability to analyse the underlying drivers of a patient's disease as the VTX-1 moves towards commercialisation."

The VTX-1 system, introduced earlier this year, offers one of the most sophisticated ways to collect and analyse CTCs, which provide the early, tell-tale signs of the onset of cancer.

Being able to identify and capture CTCs allows earlier intervention; it may also hold the key to a personalised approach to treating the killer disease, academic research has shown.

]]>
Wed, 03 Aug 2016 07:38:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/128945/netscientific-investee-company-strikes-harvard-licensing-deal-128945.html
<![CDATA[News - Netscientific hails Wanda’s new medical director ]]> http://www.proactiveinvestors.co.uk/companies/news/128682/netscientific-hails-wandas-new-medical-director-128682.html Shares in AIM- listed biomedical firm Netscientific PLC (LON:NSCI) ticked higher as it hailed the appointment of a renowned cardiologist as medical director at its California- based portfolio firm Wanda.

She is Dr Suzanne Steinbaum, a board-certified cardiologist and well-known national advocate for women's heart health, the group said.

Wanda is a digital analytics software group, whose aim is to reduce US hospital admissions.

It has developed a way to digitally monitor people with congestive heart failure and other chronic conditions, so that specialists can monitor risk and lower readmissions.

Dr Steinbaum said: "Wanda is at the forefront of a critical turning point in healthcare, in which patient engagement is essential to successful outcomes.

"I have devoted my entire career to the treatment of heart disease through early detection, education, and prevention."

She added :"While heart disease is 80 to 90% preventable, lifestyle changes are critical, and this is where Wanda comes in."

François R. Martelet, chief executive at NetScientific said: "Dr Steinbaum's extensive clinical experience and background in cardiology will make her a valuable addition to Wanda's already distinguished team."

Shares in NetScientific added 0.67% to stand at 75.5p a pop.

]]>
Wed, 27 Jul 2016 08:23:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/128682/netscientific-hails-wandas-new-medical-director-128682.html
<![CDATA[News - NetScientific ‘totally revitalised’ under Francois Martelet, says chairman Sir Richard Sykes ]]> http://www.proactiveinvestors.co.uk/companies/news/127092/netscientific-totally-revitalised-under-francois-martelet-says-chairman-sir-richard-sykes-127092.html NetScientific Plc’s (LON:NSCI) management team and portfolio focus have been totally revitalised by Francois Martelet, who took up the position of chief executive last June.

That’s the view of the company’s chairman Sir Richard Sykes ahead of the company’s Capital Markets Day at the London Stock Exchange, which happens today.

“We now have a focused portfolio of assets which are close to commercialisation and which offer the scope for significant value creation,” Sykes said in a statement.

“We look forward to highlighting the key jewels in our crown, and to explaining how they offer opportunities both to provide patient benefit and shareholder value."

Sykes and Martelet will outline to attending investors the next steps for NetScientific in maximising value from its portfolio companies. The LSE organised event will also feature representatives from the businesses that NetScientific is invested in.

In a separate statement, NetScientific announced the appointment of Dr Massimo Cristofanilli by portfolio company Vortex Biosciences to be chairman of its newly formed scientific advisory board.

"Vortex Biosciences is at a pivotal point as its circulating tumour cell enrichment system, the VTX-1, moves towards commercialisation,” Martelet said.

“The appointment of Dr. Cristofanilli, who will be joining to spearhead the creation of Vortex's world class Scientific Advisory Board, will help underpin their clinical strategy as the company moves through this transformational period."

]]>
Tue, 14 Jun 2016 08:56:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/127092/netscientific-totally-revitalised-under-francois-martelet-says-chairman-sir-richard-sykes-127092.html
<![CDATA[News - NetScientific invests in PDS Biotech ]]> http://www.proactiveinvestors.co.uk/companies/news/126822/netscientific-invests-in-pds-biotech-126822.html Healthcare investment company NetScientific PLC (LON:NSCI) has invested a further US$500,000 in immunotherapeutic drug development company PDS Biotechnology.

The money will help fund the Phase II trials of PDS’s Versamune cancer treatment technology, following the successful Phase I trials back in April.

“The promising results from PDS’s Phase I results have provided positive validation of the Versamune T-cell activating platform technology,” said NetScientific chief executive Francois Martelet.

PDS operates within the immunotherapy field which is a hot topic in the healthcare world at the moment.

Immunotherapy involves harnessing the body’s own defence systems to help fight cancer and other infectious diseases.

Shares in NetScientific were down 1.4p, or 1.7%, to 78.6p.

]]>
Tue, 07 Jun 2016 10:39:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/126822/netscientific-invests-in-pds-biotech-126822.html
<![CDATA[Media files - ProAxsis boss “excited by the potential” of protease detection technology ]]> http://www.proactiveinvestors.co.uk/companies/stocktube/4975/proaxsis-boss-excited-by-the-potential-of-protease-detection-technology-4975.html Tue, 03 May 2016 15:00:00 +0100 http://www.proactiveinvestors.co.uk/companies/stocktube/4975/proaxsis-boss-excited-by-the-potential-of-protease-detection-technology-4975.html <![CDATA[News - NetScientific portfolio company to present at prestigious cancer conference ]]> http://www.proactiveinvestors.co.uk/companies/news/124886/netscientific-portfolio-company-to-present-at-prestigious-cancer-conference-124886.html NetScientific PLC's (LON:NSCI) portfolio company, Vortex Biosciences, will preview VTX-1 at the American Association for Cancer Research (AACR) annual meeting in New Orleans.

VTX-1 is a fully automated system for the efficient enrichment of intact circulating tumour cells (CTCs) – cells that detach from a tumour and circulate in the bloodstream - from whole blood.

CTCs can potentially reveal the recurrence of cancer or the progression of the disease earlier than alternative diagnostic methods, such as imaging.

Vortex will present data at the AACR that demonstrates the ability of its technology to rapidly collect highly enriched populations of CTCs, undamaged by labels or reagents, for colorectal and prostate cancer research.

"Empowering cancer researchers with a rapid, reliable and convenient solution to collect CTCs could advance cancer research and accelerate the development of innovative diagnostics and therapeutics,” said Gene Walther, chief executive officer (CEO) of Vortex.

NetScientific's CEO, Francois Martelet, said: "We believe Vortex's technology, which is targeting a commercial launch in early 2017, could be of great benefit to the field of cancer research by providing a rapid, reliable and convenient way to collect circulating tumour cells, accelerating the development of innovative diagnostics and therapeutics."

]]>
Mon, 18 Apr 2016 08:04:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/124886/netscientific-portfolio-company-to-present-at-prestigious-cancer-conference-124886.html
<![CDATA[Media files - Netscientific chief “encouraged” by latest trial results ]]> http://www.proactiveinvestors.co.uk/companies/stocktube/4890/netscientific-chief-encouraged-by-latest-trial-results-4890.html Wed, 13 Apr 2016 15:28:00 +0100 http://www.proactiveinvestors.co.uk/companies/stocktube/4890/netscientific-chief-encouraged-by-latest-trial-results-4890.html <![CDATA[News - NetScientific buoyed by trial results; to spend further $500k ]]> http://www.proactiveinvestors.co.uk/companies/news/124727/netscientific-buoyed-by-trial-results-to-spend-further-500k-124727.html NetScientific PLC (LON:NSCI) said it plans to invest a further US$500,000 into portfolio company PDS Biotechnology after the latter released ‘encouraging’ phase I clinical trial results.

The early-stage study of PDS0101 for human papilloma virus (HPV) related cancers is designed to assess areas such as safety and whether patients can tolerate the drug.

But it also looked at the method of action of the Versamune technology behind the treatment.

Scientists found this it overcomes a key obstacle that tends to block drugs that use the body’s own immune system to tackle diseases such as cancer.

Specifically, it was able to “efficiently access” a pathway known as MHC Class-I.

This opens the way up to train and activate a population of T-cells known as “killer” T-cells to target cancers containing specific proteins.

"We are encouraged by these promising Phase I results, which provide validation of the Versamune platform technology,” said NetScientific chief executive Francois Martelet.

"This is the first validation of the technology," Martelet told Proactive.

“As an early stage investor in PDS Biotechnology we look forward to continuing our support of the company as it looks to further corroborate the potential of PDS0101 in upcoming phase II studies in pre-cancer, cervical and head and neck cancers."

"We'll be looking to rebalance the portfolio down the road and adding a stronger therapeutics leg," he added.

NetScientific has invested US$2.5mln (£1.76mln) in PDS to date and owns 14.85% of the fledgling drug developer.

Shares dipped 2% to 74p.

---ADD CEO COMMENT, SHARE PRICE---

]]>
Wed, 13 Apr 2016 08:01:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/124727/netscientific-buoyed-by-trial-results-to-spend-further-500k-124727.html
<![CDATA[News - NetScientific PLC unveils Ian Postlethwaite as new CFO ]]> http://www.proactiveinvestors.co.uk/companies/news/124423/netscientific-plc-unveils-ian-postlethwaite-as-new-cfo-124423.html Ian Postlethwaite, the departing chief financial officer of Allergy Therapeutics PLC (LON:AGY), has pitched up at healthcare technology investor NetScientific PLC (LON:NSCI).

Postlethwaite's impending departure was announced by Allergy last month, though it was not revealed at the time which company he was moving to.

He will join NetScientific after Allergy has found and bedded in a new chief financial officer.

“His wealth of experience at board level in raising capital for listed growth companies with international operations in the healthcare sector will be a huge asset to the company as we move forward with our new focus on digital health, diagnostics and therapeutics,” said Sir Richard Sykes, chairman of NetScientific.

]]>
Tue, 05 Apr 2016 09:19:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/124423/netscientific-plc-unveils-ian-postlethwaite-as-new-cfo-124423.html
<![CDATA[News - NetScientific PLC's ProAxsis sets up scientific advisory board ]]> http://www.proactiveinvestors.co.uk/companies/news/124189/netscientific-plc-s-proaxsis-sets-up-scientific-advisory-board-124189.html Healthcare technology investor NetScientific PLC (LON:NSCI) has alerted shareholders to the formation of a scientific advisory board at its diagnostics portfolio company, ProAxsis.

The advisory board will support ProAxsis in the development of its Proteasetag activity-based immunoassays and point-of-care tests, including those designed for the detection and measurement of active Neutrophil Elastase.

"ProAxsis's ProteaseTag tests have the potential to greatly improve the routine monitoring of patients with serious chronic diseases such as cystic fibrosis and COPD,” observed Francois Martelet, NetScientific's chief executive officer.

“In bringing together this hugely respected group of clinicians specialising in CF [cystic fibrosis] and respiratory diseases, ProAxsis will ensure it has world class guidance as it continues to realise this potential," Martelet added.

]]>
Wed, 30 Mar 2016 08:39:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/124189/netscientific-plc-s-proaxsis-sets-up-scientific-advisory-board-124189.html
<![CDATA[News - NetScientific looks to plenty of catalysts ahead ]]> http://www.proactiveinvestors.co.uk/companies/news/123770/netscientific-looks-to-plenty-of-catalysts-ahead-123770.html This year has certainly started with gusto for healthcare technology investor NetScientific (LON:NSCI) as it struck two significant partnerships with big US groups in the first two months.

In addition, one of its companies was handed a big boost after its technology was endorsed by the USA's powerful National Cancer Institute.

The AIM- listed biomedical firm is invested in a portfolio of 12 companies, which it hoped to push up the value chain -  with a main focus on digital health, diagnostics and therapeutics.

According to chief executive Francois Martelet recently the two main portfolio firms driving group growth are Vortex - a California based cancer circulating cells specialist and Wanda - an analytics software group, whose aim is to reduce US hospital admissions.

Wanda has developed a way to digitally monitor people with congestive heart failure and other chronic conditions, so that specialists can monitor risk and lower readmissions.

And Wanda's traction is growing. Today (March 16), it welcomed distinguished physicians and health economics scientists, to a newly formed scientific advisory board, which will advise management.

And last month, it unveiled a significant milestone, revealing it was to partner with leading US hospital group Dignity Health, whose operations span 21 states,  to launch a software platform to improve cancer care.

That platform is called OncoServe and allows clinicians to work together to establish the most effective treatment plan and helps to reduce admin costs.

Not only does it endorse Wanda's technology but  it was the second partnership it has sealed since the start of 2016.

In January this year, Wanda also inked a deal with Chicago-based Health Resource Solutions (HRS) to provide its chronic condition digital management system.

HRS looks after more than 1,000 patients per month helping them to have a higher quality of life at home rather than in hospitals.

The first patients are expected to start using the platform in the first quarter of this year.

Such technologies are significant because in the US, the system means hospitals have to pay when patents are discharged then re-admitted.

Meanwhile, on the therapeutic development side, subsidiary PDS Biotechnology signed a co-operative research and development agreement earlier this year with the US National Cancer Institute for three phase II trials of a range of cancer immunotherapies.

It plans to invest a further US$500,000 into portfolio company PDS Biotechnology after the latter released ‘encouraging’ phase I clinical trial results.

Martelet told Proactive, the NCI had put in significant funds, it was a "validation" of the technology and first interim data would be expected within the next two to two and a half years.

"We are encouraged by these promising Phase I results, which provide validation of the Versamune platform technology,” said NetScientific chief executive Francois Martelet.

PDS's Versamune platform allows users to design immunotherapies, which efficiently deliver tumour antigens to the patient's own immune system, while simultaneously stimulating the generation of potent tumour-killing T-cells.

The NCI research will look at early stage cancers, cervical initially, but also prostate and breast cancer.

So there's lots going on and plenty more ahead for the firm.

Shares stand on April 13 down 2% to 74p each, valuing the company at around £45mln.

 

]]>
Wed, 16 Mar 2016 15:11:00 +0000 http://www.proactiveinvestors.co.uk/companies/news/123770/netscientific-looks-to-plenty-of-catalysts-ahead-123770.html
<![CDATA[News - NetScientific PLC 's Wanda sets up scientific advisory board ]]> http://www.proactiveinvestors.co.uk/companies/news/123733/netscientific-plc-s-wanda-sets-up-scientific-advisory-board-123733.html Wanda, one of healthcare tech investor NetScientific plc’s (LON:NSCI) core investments, has formed a scientific advisory board to guide the management  team.

The board will include distinguished physicians, health economics scientists, and technologists committed to advancing clinical outcomes for individuals with chronic disease.

Wanda has developed a way to digitally monitor people with congestive heart failure and other chronic conditions.

Last month, it announced the launch of a software platform to improve cancer care in collaboration with leading US hospital group Dignity Health.

Francois Martelet, NetScientific's chief executive, said: "Wanda's technology has broad potential to simplify and improve the lives of people confronted with chronic conditions and, in the near term, to help patients with congestive heart failure and their physicians to monitor risk and predict and prevent readmission to hospital.  

“The calibre of the new SAB members is testament to the quality of the Wanda platform and we look forward to their input as Wanda develops into a world-leading digital health business."

Members of the new Wanda board include: Constanzo DiPerna, - medical director of Dignity Health Cancer Institute of Greater Sacramento; Clyde Wesp, executive clinical strategist at Jacobus Consulting; Janki Shah, founder and director of the UCLA Northwest Valley Women's Heart Health Program and Jeff Moreland, CEO and chief patient officer for Patient Engagement Advisors (PEA).

]]>
Wed, 16 Mar 2016 08:19:00 +0000 http://www.proactiveinvestors.co.uk/companies/news/123733/netscientific-plc-s-wanda-sets-up-scientific-advisory-board-123733.html
<![CDATA[News - NetScientific researcher wins top US award ]]> http://www.proactiveinvestors.co.uk/companies/news/123159/netscientific-researcher-wins-top-us-award-123159.html The founder and chief scientific advisor of NetScientific (LON:NSCI) subsidiary Vortex Biosciences has been awarded the US’s highest award for accomplishments in science and engineering.

Professor Dino Di Carlo received the Presidential award for devising a first-of-its-kind technique to quickly separate rare and information-rich circulating tumour cells from common blood cells.

Vortex was set up in 2012 to commercialise this ‘liquid biopsy’ technique for in applications such as diagnosis, treatment selection and monitoring, compound discovery and next generation sequencing.

Francois Martelet, NetScientific’s chief executive, said: “Vortex is our lead diagnostics company and we are delighted for Dino Di Carlo to have received this outstanding recognition for his work.

“This further endorses Vortex's core technology as we continue to accelerate its development towards a potential best-in-class technology."

]]>
Tue, 01 Mar 2016 15:08:00 +0000 http://www.proactiveinvestors.co.uk/companies/news/123159/netscientific-researcher-wins-top-us-award-123159.html
<![CDATA[News - NetScientific’s Wanda to partner with Dignity Health ]]> http://www.proactiveinvestors.co.uk/companies/news/123069/netscientifics-wanda-to-partner-with-dignity-health-123069.html Mon, 29 Feb 2016 08:22:00 +0000 http://www.proactiveinvestors.co.uk/companies/news/123069/netscientifics-wanda-to-partner-with-dignity-health-123069.html <![CDATA[Media files - Netscientific CEO: New PDS deal validates immunotherapy platform ]]> http://www.proactiveinvestors.co.uk/companies/stocktube/4636/netscientific-ceo-new-pds-deal-validates-immunotherapy-platform-4636.html Wed, 10 Feb 2016 11:19:00 +0000 http://www.proactiveinvestors.co.uk/companies/stocktube/4636/netscientific-ceo-new-pds-deal-validates-immunotherapy-platform-4636.html <![CDATA[News - NetScientific government contract to commence Phase II trials ]]> http://www.proactiveinvestors.co.uk/companies/news/122335/netscientific-government-contract-to-commence-phase-ii-trials-122335.html One of NetScientific’s (LON:NSCI) portfolio companies is to partner with the US National Cancer Institute for phase II clinical trials of a novel range of cancer immunotherapies.

PDS Biotechnology has signed a co-operative research and development agreement with the NCI to develop treatments using its Versamune platform for tumour-related proteins in prostate, breast, and HPV-related cancers.

Francois Martelet, NetScientific's chief executive, said: "Securing a cooperative research and development agreement with the leading cancer research institute in the US is a landmark moment for PDS Biotechnology and a huge endorsement of its technology.”

Versamune enables the design of simple subcutaneous immunotherapies that efficiently deliver tumour antigens to the patient's own immune system, while simultaneously stimulating the generation of potent tumour-killing T-cells.

Shares in NetScientific were 1.2% lower at 85p.

]]>
Tue, 09 Feb 2016 15:19:00 +0000 http://www.proactiveinvestors.co.uk/companies/news/122335/netscientific-government-contract-to-commence-phase-ii-trials-122335.html
<![CDATA[News - NetScientific says farewell to finance chief ]]> http://www.proactiveinvestors.co.uk/companies/news/121746/netscientific-says-farewell-to-finance-chief-121746.html Biomedical firm NetScientific (LON:NSCI) said Peter Thoms, its chief financial officer, has resigned from the board to pursue new challenges, particularly in the technology sector.

He has been at the firm since inception and has been heavily involved in building the current business, the firm added.

The process to recruit a new finance chief has started and an announcement will be made in due course.

In the meantime Mark Nanovich, the current group finance director and a chartered accountant, will assume the role of interim finance chief.

]]>
Tue, 26 Jan 2016 07:54:00 +0000 http://www.proactiveinvestors.co.uk/companies/news/121746/netscientific-says-farewell-to-finance-chief-121746.html